The pandemic H1N1 influenza vaccine results in low rates of seroconversion for patients with hematological malignancies

References

• Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006;85:278–287.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention.Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59(RR-8):1–62.
   Google Scholar
• Pollyea DA, Brown JM, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol 2010;28:2481–2490.
   PubMed Web of Science ®Google Scholar
• Centkowski P, Brydak L, Machala M, et al. Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma. J Clin Immunol 2007;27:339–346.
   PubMed Web of Science ®Google Scholar
• Brydak LB, Machala M, Centkowski P, Warzocha K, Bilinski P. Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma. Vaccine 2006;24:6620–6623.
   PubMed Web of Science ®Google Scholar
• Heath RB, Fairley GH, Malpas JS. Production of antibodies against viruses in leukemia and related diseases. Br J Haematol 1964;10:365–370.
   PubMed Web of Science ®Google Scholar
• Ortbals DW, Liebhaber H, Presant CA, Van Amburg AL, Lee JY. Influenza immunization of adult patients with malignant diseases. Ann Intern Med 1977;87:552–557.
   PubMed Web of Science ®Google Scholar
• Stiver HG, Weinerman BH. Impaired serum antibody response to inactivated influenza A and B vaccine in cancer patients. Can Med Assoc J 1978 119;733–738.
   PubMed Web of Science ®Google Scholar
• Schafer AI, Churchill WH, Ames P, Weinstein L. The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine. Cancer 1979;43:25–30.
   PubMed Web of Science ®Google Scholar
• Hodges GR, Davis JW, Lewis HD, et al. Response to influenza A vaccine among high-risk patients. South Med J 1979;72:29–32.
   PubMed Web of Science ®Google Scholar
• Shildt RA, Luedke DW, Kasai G, El-Beheri S, Laham MN. Antibody response to influenza immunization in adult patients with malignant disease. Cancer 1979;44:1629–1635.
   PubMed Web of Science ®Google Scholar
• Lo W, Whimbey E, Elting L, Couch R, Cabanillas F, Bodey G. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur J Clin Microbiol Infect Dis 1993;12:778–782.
   PubMed Web of Science ®Google Scholar
• Gribabis DA, Panayiotidis P, Boussiotis VA, Hannoun C, Pangalis GA. Influenza virus vaccine in B-cell chronic lymphocytic leukemia patients. Acta Haematol 1994;91:115–118.
   PubMed Web of Science ®Google Scholar
• Bucalossi A, Marotta G, Galieni P, Bigazzi C, Valenzin PE, Dispensa E. Immunological response to influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematol 1995;93:56.
   PubMed Web of Science ®Google Scholar
• Brydak LB, Calbecka M. Immunogenicity of influenza vaccine in patients with hemato-oncological disorders. Leuk Lymphoma 1999;32:369–374.
   PubMed Web of Science ®Google Scholar
• Robertson JD, Nagesh K, Jowitt SN, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumonia and Haemophilus influenza type B in patients with multiple myeloma. Br J Cancer 2000;82:1261–1265.
   PubMed Web of Science ®Google Scholar
• Rapezzi D, Sticchi L, Racchi O, Mangerini R, Ferraris AM, Gaetani GF. Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma. Eur J Haematol 2003;70:225–230.
   PubMed Web of Science ®Google Scholar
• Mazza JJ, Yale SH, Arrowood JR, et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res 2005;3:214–220.
   PubMedGoogle Scholar
• Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol 2005;130:96–98.
   PubMed Web of Science ®Google Scholar
• Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03(A)-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010;28:1740–1745.
   PubMed Web of Science ®Google Scholar
• Arepanrix™ H1N1: ASO3-adjuvanted H1N1 pandemic influenza vaccine.Product information leaflet. Mississauga: GlaxoSmithKline Inc.; 2009.
   Google Scholar
• Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999;37:937–943.
   PubMed Web of Science ®Google Scholar
• Steele TA. Chemotherapy-induced immunosuppression and reconstitution of immune function. Leuk Res 2002;26:411–414.
   PubMed Web of Science ®Google Scholar
• Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004;5:292–302.
   PubMed Web of Science ®Google Scholar
• Vogel FR, Caillet C, Kusters IC, Haensler J. Emulsion-based adjuvants for influenza vaccines. Expert Rev Vaccines 2009;8:483–492.
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003;49:177–184.
   PubMed Web of Science ®Google Scholar
• Baldo V, Baldovin T, Floreani A, Fragapane E, Trivello R; Family Medicine Group. Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J Clin Immunol 2007;27:542–547.
   PubMed Web of Science ®Google Scholar
• Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006;24:1159–1169.
   PubMed Web of Science ®Google Scholar
• Hobson D, Baker FA, Curry RL, Beare AS, Massey PM. The efficacy of live and inactivated vaccines of Hong Kong influenza virus in an industrial community. A report to the medical research council committee on influenza and other respiratory virus vaccines. J Hyg (Lond) 1973;71:641–647.
   PubMedGoogle Scholar
• Potter CW, Jennings R, Nicholson DA, Tyrrell DAJ, Dickinson KG. Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. J Hyg (Lond) 1977;79:321–332.
   PubMedGoogle Scholar
• Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979;35:69–75.
   PubMed Web of Science ®Google Scholar